Clinical Trial Update: Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the combination of Nivolumab and Ibrutinib in relapsed or refractory central nervous system lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System B-cell Non-hodgkin Lymphoma
• Central Nervous System Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma | Phase 2 | Status: COMPLETED